DUBLIN--(BUSINESS WIRE)--The "Pharmaceuticals
for Women's Health: Global Markets to 2023" report has been
added to ResearchAndMarkets.com's offering.
While women's health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders.
- Detailed overview of the global markets for pharmaceuticals for women's health
- Country specific data and analysis for United States, Mexico, Germany, U.K., France, China, India, Japan, Middle East and Africa
- A look at the regulatory environment which has been a driving force in the drug development industry
- Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications
- A relevant patent analysis within the sector
- Comprehensive company profiles of major Players in the Market including AbbVie Inc., Allergan PLC, Amgen Inc., Bayer Ag., Eli Lilly and Company, Johnson & Johnson Inc., Novo Nordisk and Pfizer Inc.
- Abbvie Inc.
- Allergan Plc.
- Amgen Inc.
- Bayer AG
- Daiichi Sankyo Company. Ltd.
- Eli Lilly And Company
- Johnson & Johnson Inc.
- Merck & Co. Inc.
- Merck KGaA
- Novo Nordisk
- Pfizer Inc.
Key Topics Covered
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Technologies and Global Markets Overview
Chapter 4 Pipeline Assessment and Analysis
Chapter 5 Regulatory Structure
Chapter 6 Market Breakdown by Women's Health Disorders
Chapter 7 Market Breakdown by Region
Chapter 8 Competitive Landscape and Key Developments
Chapter 9 Company Profiles
Chapter 10 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/tgxdzm/pharmaceuticals?w=4